{"log_id": 5598452075138974883, "direction": 0, "words_result_num": 46, "words_result": [{"probability": {"variance": 9.2e-05, "average": 0.997284, "min": 0.944684}, "location": {"width": 780, "top": 174, "height": 30, "left": 212}, "words": "膜阈提高。其他眼底改变包括视神经乳头苍白和萎缩,视网膜小动脉变细,视网"}, {"probability": {"variance": 0.000105, "average": 0.995513, "min": 0.943662}, "location": {"width": 776, "top": 203, "height": 27, "left": 212}, "words": "膜周围细颗粒状色素紊乱以及晚期出现凸出型脉络膜。④视野缺损:中心周围或"}, {"probability": {"variance": 0.00387, "average": 0.985601, "min": 0.6272}, "location": {"width": 773, "top": 231, "height": 28, "left": 215}, "words": "中心旁盲点、中心盲点伴视敏度下降、罕见视野狭窄。归因于视网膜病变的最常"}, {"probability": {"variance": 0.000771, "average": 0.992987, "min": 0.838751}, "location": {"width": 774, "top": 259, "height": 29, "left": 214}, "words": "见的视觉症状是:阅读及视物困难(遗漏词、字母或部分物体),畏光,远距视"}, {"probability": {"variance": 3.3e-05, "average": 0.997255, "min": 0.97374}, "location": {"width": 777, "top": 287, "height": 30, "left": 212}, "words": "觉模糊,中心或周围视野有区域消失或变黑,闪光及划线。视网膜病变似具有剂"}, {"probability": {"variance": 0.000204, "average": 0.996068, "min": 0.91454}, "location": {"width": 776, "top": 316, "height": 32, "left": 212}, "words": "量相关性,在每日1次治疗数月(罕见)至数年时出现;少数病例在抗疟药治疗"}, {"probability": {"variance": 0.006887, "average": 0.978769, "min": 0.509433}, "location": {"width": 776, "top": 346, "height": 32, "left": 212}, "words": "停止后数年报道。用4—氨基喹啉化合物治疗疟疾每周给药1次,长期应用未见"}, {"probability": {"variance": 5e-06, "average": 0.998594, "min": 0.990679}, "location": {"width": 776, "top": 374, "height": 34, "left": 211}, "words": "视网膜病变。视网膜改变患者可能有视觉症状或者没有症状(伴或不伴视野改"}, {"probability": {"variance": 3.8e-05, "average": 0.996987, "min": 0.969285}, "location": {"width": 774, "top": 405, "height": 31, "left": 212}, "words": "变),罕见不伴视网膜明显改变的视觉盲点或视野缺损。视网膜病变即使停药后"}, {"probability": {"variance": 0.000101, "average": 0.996763, "min": 0.94019}, "location": {"width": 776, "top": 433, "height": 30, "left": 211}, "words": "仍会进展。有许多患者早期的视网膜病变(黄斑色素沉着,有时伴中心、视野缺"}, {"probability": {"variance": 1.6e-05, "average": 0.997464, "min": 0.983691}, "location": {"width": 776, "top": 461, "height": 32, "left": 211}, "words": "损)在治疗中止后完全消失或缓解。对红色视标出现中心、旁盲点(有时称:前"}, {"probability": {"variance": 2.4e-05, "average": 0.998373, "min": 0.970699}, "location": {"width": 775, "top": 489, "height": 33, "left": 211}, "words": "黄斑病变)是早期视网膜机能障碍的征兆,停药后通常是可逆的。少数视网膜改"}, {"probability": {"variance": 1e-05, "average": 0.998378, "min": 0.983765}, "location": {"width": 775, "top": 519, "height": 30, "left": 210}, "words": "变的病例,据报道发生在仅接受羟氯喹的患者,通常包括在定期眼科检查中发现"}, {"probability": {"variance": 5.6e-05, "average": 0.996995, "min": 0.95844}, "location": {"width": 805, "top": 544, "height": 38, "left": 210}, "words": "的视网膜色素沉着改变,某些病例也存在视野缺损,已报道1例延迟性视网膜"}, {"probability": {"variance": 2e-06, "average": 0.99904, "min": 0.99395}, "location": {"width": 408, "top": 575, "height": 28, "left": 206}, "words": "病变伴随视觉缺失,发生在停用羟氯喹后"}, {"probability": {"variance": 8e-05, "average": 0.996264, "min": 0.960781}, "location": {"width": 728, "top": 601, "height": 35, "left": 258}, "words": "4)皮肤反应:头发变白、脱发、瘙痒、皮肤及粘膜色素沉着、皮疹(荨麻"}, {"probability": {"variance": 0.000118, "average": 0.995812, "min": 0.937924}, "location": {"width": 754, "top": 630, "height": 35, "left": 207}, "words": "疹、麻疹样、苔藓样、斑丘疹、紫癜、离心形环形红斑和剥脱性皮炎)。"}, {"probability": {"variance": 0.003187, "average": 0.98281, "min": 0.684682}, "location": {"width": 730, "top": 658, "height": 37, "left": 257}, "words": "()血液学反应:如再生障碍性贫血、粒细胞缺乏、白细胞减少,血小板减"}, {"probability": {"variance": 0.022923, "average": 0.941101, "min": 0.385009}, "location": {"width": 619, "top": 686, "height": 35, "left": 207}, "words": "少,葡萄糖6—磷酸脱氢酶(G6-PD)缺乏的个体发生溶血"}, {"probability": {"variance": 0.000544, "average": 0.993187, "min": 0.873239}, "location": {"width": 615, "top": 716, "height": 35, "left": 257}, "words": "6)肠胃道反应:食欲不振、恶心、呕吐、腹泻及腹部痛性痉挛"}, {"probability": {"variance": 0.002184, "average": 0.982143, "min": 0.782831}, "location": {"width": 730, "top": 744, "height": 38, "left": 257}, "words": "7)其他:体重减轻,倦怠,卟啉症恶化或加速以及非光敏性牛皮癣。局部"}, {"probability": {"variance": 1.1e-05, "average": 0.998041, "min": 0.988179}, "location": {"width": 472, "top": 773, "height": 34, "left": 206}, "words": "报道罕见心肌病变,其与羟氯喹的关系尚不明确"}, {"probability": {"variance": 2e-06, "average": 0.998967, "min": 0.99706}, "location": {"width": 62, "top": 804, "height": 25, "left": 227}, "words": "禁忌】"}, {"probability": {"variance": 0.007215, "average": 0.978627, "min": 0.50948}, "location": {"width": 729, "top": 830, "height": 39, "left": 254}, "words": "()对任何4-氨基喹啉化合物治疗可引起的视网膜或视野改变的患者禁"}, {"probability": {"variance": 0, "average": 0.999029, "min": 0.999029}, "location": {"width": 28, "top": 860, "height": 28, "left": 204}, "words": "用"}, {"probability": {"variance": 0.000159, "average": 0.994566, "min": 0.945658}, "location": {"width": 448, "top": 890, "height": 30, "left": 260}, "words": "2)已知对4氨基喹啉化合物过敏的患者禁用"}, {"probability": {"variance": 7e-06, "average": 0.998018, "min": 0.992288}, "location": {"width": 119, "top": 917, "height": 25, "left": 211}, "words": "【注意事项】"}, {"probability": {"variance": 0.004694, "average": 0.981678, "min": 0.716328}, "location": {"width": 340, "top": 947, "height": 27, "left": 259}, "words": "1)本品应放在儿童无法取到的地方"}, {"probability": {"variance": 0.055369, "average": 0.600779, "min": 0.365471}, "location": {"width": 33, "top": 946, "height": 31, "left": 857}, "words": "7"}, {"probability": {"variance": 0.000633, "average": 0.993351, "min": 0.853559}, "location": {"width": 725, "top": 972, "height": 41, "left": 256}, "words": "2)牛皮癣患者及卟啉症患者使用本品均可使原病症加重。故本品不应使用"}, {"probability": {"variance": 0.008436, "average": 0.980505, "min": 0.495183}, "location": {"width": 652, "top": 1000, "height": 39, "left": 204}, "words": "于这些患者,除非根据医师判断,患者的得益将超过其可能的风险"}, {"probability": {"variance": 9.5e-05, "average": 0.996686, "min": 0.947904}, "location": {"width": 591, "top": 1031, "height": 36, "left": 256}, "words": "3)医师在开出本品处方前应当完全熟悉本说明书的全部内容"}, {"probability": {"variance": 1.6e-05, "average": 0.998041, "min": 0.980304}, "location": {"width": 724, "top": 1059, "height": 39, "left": 257}, "words": "4)接受长期或高剂量治疗的某些患者,已观察到有不可逆视网膜损伤,据"}, {"probability": {"variance": 1e-06, "average": 0.99882, "min": 0.996194}, "location": {"width": 316, "top": 1088, "height": 31, "left": 202}, "words": "报道视网膜病变具有剂量相关性"}, {"probability": {"variance": 0.000112, "average": 0.994231, "min": 0.94527}, "location": {"width": 727, "top": 1115, "height": 41, "left": 252}, "words": "()服用本品应进行初次(基线)以及定期(每3个月1次)的眼科检查(包"}, {"probability": {"variance": 1.1e-05, "average": 0.997569, "min": 0.988191}, "location": {"width": 467, "top": 1145, "height": 33, "left": 200}, "words": "括视敏度、输出裂隙灯、眼底镜以及视野检查)"}, {"probability": {"variance": 3.4e-05, "average": 0.996378, "min": 0.981005}, "location": {"width": 704, "top": 1173, "height": 40, "left": 254}, "words": "6)如果视敏度、视野或视网膜黄斑区出现任何异常的迹象(如色素变化"}, {"probability": {"variance": 9e-06, "average": 0.998573, "min": 0.981964}, "location": {"width": 776, "top": 1201, "height": 42, "left": 203}, "words": "失去中心凹反射)或出现任何视觉症状(如闪光和划线),且不能用调节困难或"}, {"probability": {"variance": 4.4e-05, "average": 0.997069, "min": 0.970011}, "location": {"width": 778, "top": 1232, "height": 39, "left": 198}, "words": "角膜混浊完全解释时,应当立即停药,并密切观察其可能的进展。即使在停止治疗"}, {"probability": {"variance": 8.9e-05, "average": 0.995343, "min": 0.967249}, "location": {"width": 452, "top": 1262, "height": 33, "left": 198}, "words": "之后,视网膜改变(及视觉障碍)仍可能进展"}, {"probability": {"variance": 8.9e-05, "average": 0.995636, "min": 0.950133}, "location": {"width": 717, "top": 1291, "height": 37, "left": 250}, "words": "()使用本品长期治疗的所有患者应定期随访和检查,包括检查膝和踝反射"}, {"probability": {"variance": 2e-05, "average": 0.998417, "min": 0.976831}, "location": {"width": 563, "top": 1319, "height": 33, "left": 200}, "words": "以及发现肌肉软弱的任何迹象。如发现肌软弱,应当停药"}, {"probability": {"variance": 0.000351, "average": 0.994697, "min": 0.89919}, "location": {"width": 684, "top": 1347, "height": 37, "left": 248}, "words": "()肝病或醇中毒患者,或者与已知有肝脏毒性的药物合用时,应慎用"}, {"probability": {"variance": 5e-05, "average": 0.996737, "min": 0.964869}, "location": {"width": 729, "top": 1376, "height": 39, "left": 249}, "words": "()对长期接受本品治疗的患者应定期作血细胞计数。如出现不能归因于所"}, {"probability": {"variance": 2e-06, "average": 0.99895, "min": 0.994353}, "location": {"width": 514, "top": 1406, "height": 31, "left": 199}, "words": "治疾病的任何严重血液障碍,应当考虑停药。缺乏G"}, {"probability": {"variance": 0.004374, "average": 0.972803, "min": 0.797894}, "location": {"width": 197, "top": 1414, "height": 27, "left": 778}, "words": "PD(葡萄糖—6"}], "language": 3}